Comparative Pharmacology
Head-to-head clinical analysis: ELESTAT versus LASTACAFT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELESTAT versus LASTACAFT.
ELESTAT vs LASTACAFT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective histamine H1 receptor antagonist; inhibits histamine release from mast cells.
Selective histamine H1 receptor antagonist; inhibits mast cell degranulation and reduces release of inflammatory mediators.
1 drop (0.05% ophthalmic solution) in the affected eye twice daily approximately every 12 hours.
1 drop in each affected eye twice daily (approximately every 8 hours)
None Documented
None Documented
Terminal elimination half-life is approximately 8-12 hours in healthy adults; clinically, twice-daily dosing maintains therapeutic concentrations.
Terminal elimination half-life is approximately 2 hours; clinically, dosing is twice daily.
Primarily renal excretion of unchanged drug (approx. 60-70%) and metabolites; biliary/fecal excretion accounts for 20-30%.
Renal: approximately 70% as unchanged drug; fecal: approximately 30% as metabolites.
Category C
Category C
Ophthalmic Antihistamine
Ophthalmic Antihistamine